Monitor for partnership announcements or Phase 2b trial initiation details from the BIO International Convention in San Diego. The stock is highly speculative with a $7M market cap and no approved products; any positive data or deal could drive significant volatility, but failure to secure a partner or negative trial results would be highly detrimental.
Price Chart
Executive Summary
Can-Fite announced plans to advance its pancreatic cancer drug Namodenoson into a Phase 2b combination study with immunotherapy, following encouraging Phase 2a data showing stable disease in >30% of evaluable patients and 35% still on therapy. The company is also pursuing partnership negotiations with oncology companies at the BIO International Convention. This is a clinical-stage update with no new financial data or revenue.
Key Facts
- Phase 2a study showed stable disease in >30% of evaluable patients with advanced pancreatic adenocarcinoma
- 35% of patients remain on therapy and follow-up
- Phase 2b will evaluate Namodenoson in combination with immunotherapy
- Company has entered confidentiality agreements with several pharmaceutical companies for potential partnerships
- Namodenoson has FDA Orphan Drug Designation for pancreatic cancer
- No financial terms, revenue, or earnings data disclosed
Financial Impact
No financial figures disclosed; clinical-stage update with no revenue impact
Risk Factors
- No revenue or approved products; company relies on dilutive financing
- Phase 2b trial may fail to show efficacy or face enrollment delays
- Partnership negotiations may not materialize into definitive agreements
- History of losses and need for additional capital to fund operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-055438 |
| Document: ea0290308-6k_canfite.htm | 0001213900-26-055438 |
| Document: 0001213900-26-055438-index-headers.html | 0001213900-26-055438 |
| Document: 0001213900-26-055438-index.html | 0001213900-26-055438 |
| Document: 0001213900-26-055438.txt | 0001213900-26-055438 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.95 | awaiting T+5 | — | $1.65 (−15.38%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.65 (+28.26%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.65 (−24.66%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.65 (−29.79%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.65 (+30.08%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.65 (−53.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers